Wall Street brokerages predict that Sophiris Bio (NASDAQ:SPHS) will post earnings of ($0.13) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sophiris Bio’s earnings, with estimates ranging from ($0.17) to ($0.10). Sophiris Bio reported earnings of ($0.09) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 44.4%. The business is scheduled to report its next earnings results on Thursday, August 9th.
According to Zacks, analysts expect that Sophiris Bio will report full year earnings of ($0.51) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.39). For the next financial year, analysts anticipate that the company will post earnings of ($0.53) per share, with EPS estimates ranging from ($0.65) to ($0.40). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that that provide coverage for Sophiris Bio.
Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02.
A number of research firms have commented on SPHS. Maxim Group upped their price target on Sophiris Bio to $8.00 and gave the company a “buy” rating in a research report on Tuesday, May 15th. ValuEngine upgraded Sophiris Bio from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. Finally, HC Wainwright set a $6.00 price target on Sophiris Bio and gave the company a “buy” rating in a research report on Thursday, March 22nd.
SPHS stock traded down $0.07 during midday trading on Friday, reaching $3.72. 5,514 shares of the stock were exchanged, compared to its average volume of 300,396. The firm has a market capitalization of $112.01 million, a P/E ratio of -9.45 and a beta of 1.38. Sophiris Bio has a 52 week low of $1.80 and a 52 week high of $4.05. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.30.
Large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in shares of Sophiris Bio in the 4th quarter valued at about $312,000. Virtu Financial LLC lifted its stake in shares of Sophiris Bio by 389.7% in the 4th quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock valued at $385,000 after purchasing an additional 135,119 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Sophiris Bio in the 4th quarter valued at about $453,000. 5.67% of the stock is currently owned by institutional investors.
Sophiris Bio Company Profile
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Get a free copy of the Zacks research report on Sophiris Bio (SPHS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.